MX2009002905A - Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos. - Google Patents

Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.

Info

Publication number
MX2009002905A
MX2009002905A MX2009002905A MX2009002905A MX2009002905A MX 2009002905 A MX2009002905 A MX 2009002905A MX 2009002905 A MX2009002905 A MX 2009002905A MX 2009002905 A MX2009002905 A MX 2009002905A MX 2009002905 A MX2009002905 A MX 2009002905A
Authority
MX
Mexico
Prior art keywords
sup
alkyl
hydrogen
aryl
pharmaceutically acceptable
Prior art date
Application number
MX2009002905A
Other languages
English (en)
Inventor
Kamlesh Jyotindra Padiya
Nabajyoti Deka
Swapnil Ramesh Bajare
Rhushikesh Arun Kulkarni
Taj Usman Khan
Sivaramakrishnan Hariharan
Rosalind Adaikalasamy Marita
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of MX2009002905A publication Critical patent/MX2009002905A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona nuevos compuestos representados por la fórmula general (I); en donde AR es una porción de quinolina o isoquinolina que está sustituida o insustituida; B es -O-, -S-, o -NH-; R1 es hidrógeno o S(O)2R4; R2 es S(O)2R4; C(O)OR5; o C(O) (CH2)n-C(O)OR6; R3 es halógeno, ciano, C(O)OR7, o C(O)NR8R9; R4 es arilo; R5 es (C1-C6)alquilo o arilo; R6 es hidrógeno. (C1-C4)alquiko o arilo; R7 es hidrógeno o (C1-C4)alquilo; R8 y R9 son independientemente hidrógeno o (C1-C6)alquilo; n es un número entero de 1-3; y una sal o solvato farmacéuticamente aceptables de los mismos, sus sales farmacéuticamente aceptables y sus solvatos farmacéuticamente aceptables de los mismos, que son útiles en el tratamiento de trastornos metabólicos relacionados con la resistencia a insulina o hiperglicemia. La invención también se refiere a un proceso para la elaboración de compuestos de la fórmula (I) y composiciones farmacéuticas que los contienen.
MX2009002905A 2006-09-21 2007-09-20 Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos. MX2009002905A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84619406P 2006-09-21 2006-09-21
US87567206P 2006-12-18 2006-12-18
PCT/IB2007/053812 WO2008035306A1 (en) 2006-09-21 2007-09-20 3 -amino- pyridine derivatives for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
MX2009002905A true MX2009002905A (es) 2009-06-19

Family

ID=39048032

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009002906A MX2009002906A (es) 2006-09-21 2007-09-20 Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
MX2009002905A MX2009002905A (es) 2006-09-21 2007-09-20 Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009002906A MX2009002906A (es) 2006-09-21 2007-09-20 Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.

Country Status (19)

Country Link
US (5) US8030324B2 (es)
EP (2) EP2094687A1 (es)
JP (2) JP2010504321A (es)
KR (2) KR20090075827A (es)
AR (2) AR062940A1 (es)
AT (1) ATE496890T1 (es)
AU (2) AU2007298540B2 (es)
BR (2) BRPI0717106A2 (es)
CA (2) CA2663943A1 (es)
DE (1) DE602007012299D1 (es)
DK (1) DK2094663T3 (es)
IL (2) IL197694A0 (es)
MX (2) MX2009002906A (es)
NZ (2) NZ576197A (es)
PL (1) PL2094663T3 (es)
PT (1) PT2094663E (es)
RU (2) RU2460729C2 (es)
TW (2) TW200817364A (es)
WO (2) WO2008035306A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013117963A1 (en) 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
WO2014207508A1 (en) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Pyridyl compound suitable for the treatment of metabolic disorders
BR122023004130B1 (pt) 2013-06-27 2023-12-12 Pfizer Inc Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1
EA028614B1 (ru) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084085A (en) * 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
NZ530833A (en) 1999-06-30 2005-08-26 Tularik Inc Compounds for the modulation of PPARgamma activity
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU7163701A (en) * 2000-06-28 2002-01-08 Tularik Inc Quinolinyl and benzothiazolyl ppar-gamma modulators
CA2526204A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
BRPI0514150A (pt) * 2004-08-06 2007-11-27 Otsuka Pharma Co Ltd composto aromático ou um sal do mesmo, método para produzir o mesmo, e, composição farmacêutica para tratar a fibrose
MX2007003913A (es) * 2004-10-04 2007-05-21 Hoffmann La Roche Alquil-piridinas como inhibidores de 11 beta para diabetes.

Also Published As

Publication number Publication date
AR062941A1 (es) 2008-12-17
ATE496890T1 (de) 2011-02-15
AU2007298540B2 (en) 2013-02-21
TW200820970A (en) 2008-05-16
US20090247574A1 (en) 2009-10-01
AU2007298539B2 (en) 2013-05-02
EP2094663B1 (en) 2011-01-26
RU2009114545A (ru) 2010-10-27
US20130040988A1 (en) 2013-02-14
US8269010B2 (en) 2012-09-18
RU2460729C2 (ru) 2012-09-10
AR062940A1 (es) 2008-12-17
WO2008035305A8 (en) 2009-03-12
EP2094687A1 (en) 2009-09-02
WO2008035305A2 (en) 2008-03-27
JP2010504322A (ja) 2010-02-12
IL197695A0 (en) 2009-12-24
EP2094663A2 (en) 2009-09-02
DK2094663T3 (da) 2011-04-26
WO2008035305A3 (en) 2008-06-12
CA2663943A1 (en) 2008-03-27
MX2009002906A (es) 2009-06-30
NZ576196A (en) 2011-12-22
IL197694A0 (en) 2009-12-24
RU2448093C2 (ru) 2012-04-20
US20120309786A1 (en) 2012-12-06
AU2007298539A1 (en) 2008-03-27
US20100022554A1 (en) 2010-01-28
JP2010504321A (ja) 2010-02-12
US20110312970A1 (en) 2011-12-22
NZ576197A (en) 2011-12-22
PL2094663T3 (pl) 2011-07-29
PT2094663E (pt) 2011-04-19
AU2007298540A1 (en) 2008-03-27
JP5331953B2 (ja) 2013-10-30
KR20090074775A (ko) 2009-07-07
RU2009114544A (ru) 2010-10-27
WO2008035306A1 (en) 2008-03-27
BRPI0718510A2 (pt) 2013-11-19
CA2663901A1 (en) 2008-03-27
KR20090075827A (ko) 2009-07-09
US8030324B2 (en) 2011-10-04
US8349862B2 (en) 2013-01-08
BRPI0717106A2 (pt) 2013-10-08
TW200817364A (en) 2008-04-16
DE602007012299D1 (de) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
TW200716528A (en) Cyclopropanecarboxamide derivatives
PH12015501925A1 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MX2009002905A (es) Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.
BR112014030577B1 (pt) Dihidronaftiridinas e compostos relacionados, bem como composições farmacêuticas compreendendo os mesmos
JP2015507606A (ja) 抗癌および抗増殖作用を示すピリドンアミドおよび類似体
JP7463318B2 (ja) ６員アザヘテロ環を含有するデルタ－オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
PT2287155E (pt) Composto de aciltioureia ou um seu sal, e sua utilização
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
AU2016382372B2 (en) Sulfonamide derivative and preparation method and use thereof
BRPI0418368A (pt) derivados de (3-oxo-3,4-dihidro-quinoxalin2-ilamino)-benzamida e compostos afins, como inibidores de glicogênio fosforilase para o tratamento de diabetes e obesidade
JP6380777B2 (ja) ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
CA2865875A1 (en) Piperidine compound or salt thereof
CN110267940A (zh) 四取代的烯烃化合物和它们的用途
JP2015502371A5 (es)
CA3202763A1 (en) Benzene ring compound and use thereof
JP6343034B2 (ja) ナフチリジンジオン誘導体
MA27917A1 (fr) Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPWO2009119167A1 (ja) 抗ｒｎａウイルス作用を有するアニリン誘導体
RU2008129623A (ru) Ингибиторы ccr9 активности
JP2021509399A (ja) インドールアミン−２，３−ジオキシゲナーゼ阻害剤およびその調製方法と使用
RU2007105558A (ru) Новые производные 2, 6-диаминопиридин-3-она
KR20080077889A (ko) 약제학적 항암 조성물

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status

Owner name: PIRAMAL ENTERPRISES LIMITED.*

PD Change of proprietorship

Owner name: PIRAMAL ENTERPRISES LIMITED.*